Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PacBio)
Filing Type: Form 8-K (Current Report)
Date of Report: November 1, 2018
Event: Entry into a Material Definitive Agreement (Merger Agreement) with Illumina, Inc.
Key Financial Metrics and Transaction Terms
This filing details a proposed acquisition rather than periodic financial performance. Key financial terms include:
- Merger Consideration: $8.00 in cash per share of PacBio common stock.
- Equity Treatment: Outstanding restricted stock units and stock options will convert to cash based on the merger consideration (or the spread for options).
- Termination Fee (PacBio to Illumina): $43.00 million, payable if PacBio accepts a superior offer, withdraws its recommendation, or enters a competing transaction within one year of termination.
- Termination Fee (Illumina to PacBio): $98.00 million, payable if the agreement is terminated after November 1, 2019, due to antitrust issues, provided other closing conditions are met.
- Financing: The transaction is not subject to any financing condition.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for PacBio.
Material Changes and Agreements
On November 1, 2018, PacBio entered into an Agreement and Plan of Merger with Illumina, Inc. and its wholly owned subsidiary, FC Ops Corp. Upon consummation, PacBio will become a wholly owned subsidiary of Illumina. Key changes include:
- Bylaws Amendment: The Board amended the Bylaws to designate state and federal courts in Delaware as the exclusive forum for governance disputes.
- Voting Agreement: Eleven significant stockholders (representing approximately 1.98% of outstanding shares as of October 30, 2018) agreed to vote in favor of the merger and waive appraisal rights.
- Restrictions: PacBio is restricted from soliciting alternative transactions or providing confidential information regarding such transactions during the pendency of the merger.
Guidance, Outlook, and Risks
Outlook and Conditions:
- Consummation is subject to PacBio stockholder approval.
- Antitrust clearance is required under the U.S. Hart-Scott-Rodino Act and certain non-U.S. jurisdictions.
- The agreement includes a termination right if the merger is not completed by November 1, 2019, unless extended.
- Regulatory Risk: Failure to obtain antitrust approvals could trigger the $98.00 million reverse termination fee payable by Illumina.
- Competing Offers: Acceptance of a superior offer would trigger the $43.00 million termination fee payable by PacBio.
- Legal Disputes: Parties remain liable for additional damages in cases of intentional failure to fulfill conditions, material breach of covenants, or willful breach of representations.
Investor Verification Checklist
- Verify the final vote count from PacBio stockholders regarding the Merger Agreement.
- Monitor regulatory filings for antitrust clearance status in the U.S. and international jurisdictions.
- Review the definitive proxy statement for detailed financial data and risk factors not included in this 8-K.
- Confirm the status of the Voting Agreement holders and whether their 1.98% stake remains committed.
- Check for any announcements regarding competing proposals or changes to the termination fee structure.